Preclinical pipelines for cancer immunotherapies increasingly incorporate rodent models that support dual engraftment of human immune system cells and human tumors. These humanized models enable researchers to evaluate human-specific therapies, often dramatically reducing preclinical timelines while increasing the translational relevance of study results.
Importantly, there is no single best humanized mouse model. Understanding how and which humanized mouse model to apply is critical to effective preclinical immuno-oncology (IO) efforts.
In this free, two-part webinar series from Taconic Biosciences, we’ll explore how humanized mouse models enable preclinical evaluation of novel immunotherapies, with a special focus on immune cell-engaging bispecifics, checkpoint inhibition, and combinatorial preclinical strategies.
Dr. Paul Volden is a Field Application Scientist at Taconic Biosciences. He earned his PhD from the University of Chicago’s Committee on Molecular Metabolism and Nutrition and has over a decade of biological and biomedical research experience, spanning rodent model applications for cancer, metabolic disease, and cardiovascular disease. At Taconic, Dr. Volden assists researchers with in vivo model selection and study design, specializing in humanized immune system mice as preclinical models for evaluating novel immunotherapies.
© 2020 Taconic Biosciences, Inc. All rights reserved.